Jyong Biotech Ltd
MENS38.320USD
-0.420-1.08%
Market hours （ET）Quotes delayed by 15 min
2.91BMarket Cap
--P/E TTM
More Details of Jyong Biotech Ltd Company
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Jyong Biotech Ltd Info
Ticker SymbolMENS
Company nameJyong Biotech Ltd
IPO dateJun 17, 2025
CEOMr. Fu Feng Kuo
Number of employees29
Security typeOrdinary Share
Fiscal year-endJun 17
Address23F-3, No.95, Section 1, Xintai 5th, Xizhi District
CityNEW TAIPEI
Stock exchangeNASDAQ Global Market Consolidated
CountryTaiwan
Postal code221
Phone886227325205
Websitehttps://jyongbio.com/
Ticker SymbolMENS
IPO dateJun 17, 2025
CEOMr. Fu Feng Kuo
Company Executives of Jyong Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
--
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Dr. Wanwen (Angela) Su
Dr. Wanwen (Angela) Su
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Mr. Ming Tsan Hsu
Mr. Ming Tsan Hsu
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alfred Ying
Mr. Alfred Ying
Chief Financial Officer
Chief Financial Officer
4.00K
--
Dr. Fenglin Hsu
Dr. Fenglin Hsu
Director and Chief Technology Officer
Director and Chief Technology Officer
3.00K
--
Mr. Hung-Shu Fan
Mr. Hung-Shu Fan
Independent Director
Independent Director
--
--
Ms. Fu-Feng Kuo
Ms. Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer
Chairwoman of the Board and Chief Executive Officer
--
--
Dr. Wanwen (Angela) Su
Dr. Wanwen (Angela) Su
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pang-Chief Chi
Mr. Pang-Chief Chi
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Oct 27
Updated: Mon, Oct 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Other
37.80%
Shareholders
Shareholders
Proportion
Perfect Minds Co Ltd
33.34%
Laxton Investments Company Ltd
10.04%
Linkage Gladden Enterprise Ltd
9.03%
Peak Valley International Co., Ltd.
6.71%
Honest Dynasty Ltd
3.08%
Other
37.80%
Shareholder Types
Shareholders
Proportion
Corporation
62.20%
Hedge Fund
0.09%
Investment Advisor/Hedge Fund
0.07%
Investment Advisor
0.03%
Other
37.61%
Institutional Shareholding
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
5
148.54K
0.20%
+138.11K
2025Q2
7
47.29M
62.20%
+47.29M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perfect Minds Co Ltd
25.35M
33.34%
+25.35M
--
Jun 17, 2025
Laxton Investments Company Ltd
7.63M
10.04%
+7.63M
--
Jun 17, 2025
Linkage Gladden Enterprise Ltd
6.86M
9.03%
+6.86M
--
Jun 17, 2025
Peak Valley International Co., Ltd.
5.10M
6.71%
+5.10M
--
Jun 17, 2025
Honest Dynasty Ltd
2.34M
3.08%
+2.34M
--
Jun 17, 2025
Citadel Advisors LLC
70.97K
0.09%
+70.97K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
10.43K
0.01%
--
--
Aug 31, 2025
HRT Financial LP
22.92K
0.03%
+22.92K
--
Jun 30, 2025
Ying (Alfred)
4.00K
0.01%
+4.00K
--
Jun 17, 2025
Hsu (Fenglin)
3.00K
0%
+3.00K
--
Jun 17, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
